Regencell Bioscience Holdings (RGC) Cash Flow: Operating & Free Cash Flow

Regencell Bioscience Holdings Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Regencell Bioscience Holdings Limited (RGC) - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Dec 2017	Dec 2016
Operating Activities
Net Income	-	-3.58	-4.36	-5.87	-7.59	-1.35	-0.81	-0.39	112.30	170.40
Depreciation & Amortization	-	0.39	0.75	0.77	0.60	0.03	0.01	0.00	254.80	230.70
Deferred Income Tax	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.60	2.40
Stock Based Compensation	3.23	0.24	0.45	0.93	2.76	0.00	0.00	0.00	0.00	0.00
Change in Working Capital	-	0.02	-0.59	-0.51	-1.02	0.55	0.08	0.00	-35.00	-67.40
Change in Accounts Receivable	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-27.00	-7.00
Change in Inventory	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.30	1.50
Change in Accounts Payable	-	0.00	0.00	0.00	-0.07	0.00	0.00	0.00	31.10	-38.30
Change in Other Working Capital	-	0.02	-0.59	-0.51	-0.60	0.55	0.08	0.00	-37.80	-23.60
Other Operating Activities	-	0.06	-0.25	-0.28	-0.01	0.00	0.00	0.00	68.00	65.60
Net Cash from Operating Activities	-7.70	-3.11	-4.00	-4.96	-5.27	-0.77	-0.73	-0.39	409.90	410.50
Investing Activities
Capital Expenditures	-	-0.15	-0.01	-0.03	-0.78	0.00	-0.12	0.00	-250.40	-214.90
Acquisitions	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-171.60	0.00
Purchases of Investments	-	-32.48	-5.00	0.00	-10.00	0.00	0.00	0.00	0.00	0.00
Sales/Maturities of Investments	-	35.32	10.25	0.00	0.00	0.00	0.00	0.00	0.00	3.60
Other Investing Activities	-	0.00	0.00	0.09	-10.00	0.00	0.00	0.00	11.40	-12.30
Net Cash from Investing Activities	2.50	2.69	5.24	0.06	-10.78	0.00	-0.12	0.00	-410.60	-223.60
Financing Activities
Debt Repayment	-	0.00	0.00	0.00	-0.43	0.00	0.99	0.48	0.00	0.00
Common Stock Issued	-	0.00	0.00	0.00	22.67	0.00	0.00	0.00	0.00	0.00
Common Stock Repurchased	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-228.80	0.00
Other Financing Activities	-	0.00	0.10	0.13	0.16	0.44	0.00	0.00	-17.00	-160.00
Net Cash from Financing Activities	16.95	0.00	0.10	0.13	22.41	0.44	0.99	0.48	-17.00	-160.00
Summary
Effect of Forex Changes on Cash	-	-0.11	0.05	-0.08	0.00	0.00	0.00	0.00	0.00	0.00
Net Change in Cash	11.77	-0.54	1.40	-4.85	6.36	-0.33	0.14	0.09	-17.70	26.90
Cash at Beginning of Period	-	2.96	1.56	6.42	0.06	0.39	0.24	0.15	246.50	219.60
Cash at End of Period	-	2.42	2.96	1.56	6.42	0.06	0.39	0.24	228.80	246.50
Free Cash Flow	-7.70	-3.27	-4.01	-4.99	-6.05	-0.77	-0.84	-0.39	159.50	195.60

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Regencell Bioscience Holdings Cash Flow

What is Regencell Bioscience Holdings's free cash flow?

Regencell Bioscience Holdings had negative free cash flow of $7.70M in fiscal 2026 (fiscal year ended Jun 30, 2026).

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition